Clinical Trial Applications - Suspended: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Suspended | |
|---|---|---|---|---|---|
1. |
ECCT/23/10/08 | VALUE Placebo Film Study Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal Films (MATRIX-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
Not recorded |
View |
2. |
ECCT/23/10/02 | MATRIX-001 protocol A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
Not recorded |
View |
3. |
ECCT/21/11/05 | SOLIDARITY TRIAL PLUS An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. loice Ombajo Site(s) in Kenya 1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county) 2. The Nairobi Hospital (Nairobi City county) |
Not recorded |
View |
4. |
ECCT/20/04/03 | 518 & 525-SHAN6â„¢ Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants. Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age |
Principal Investigator(s) 1. Bernhards Ogutu 2. Godfrey Allan Otieno 3. Videlis Nduba 4. Lucy Chepkurui Koech 5. samuel Gurrion Ouma 6. Janet Oyieko Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county) 5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county) 6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county) 7. CRDR_Siaya Annex(Back-up site) (Siaya county) |
Not recorded |
View |
5. |
ECCT/20/05/03 | A5381 Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment |
Principal Investigator(s) 1. Victor Mudhune Site(s) in Kenya Kisumu Clinical Research Center |
Not recorded |
View |
6. |
ECCT/20/04/01 | Solidarity An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kilifi Kemri-Wellcome (Kilifi county) 2. Kenya National Hospital (Nairobi City county) 3. Coast PGH (Mombasa county) 4. The Nairobi Hospital (Nairobi City county) 5. Aga Khan University Hospital (Nairobi City county) 6. Moi Teahing and Referal Hospital (Uasin Gishu county) 7. Kenyatta University teaching research and referal hospital (Kiambu county) |
Not recorded |
View |
7. |
ECCT/19/11/01 | A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults. Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults. |
Principal Investigator(s) 1. Melissa Kapulu Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
Not recorded |
View |
8. |
ECCT/19/01/01 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Ragama Site(s) in Kenya 1. Ahero County hospital (Kisumu county) 2. Siaya County Hospital (Siaya county) |
Not recorded |
View |
9. |
ECCT/17/11/01 | MTN 034 MTN 034 A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population |
Principal Investigator(s) 1. ESTHER MUMBI MAKANGA Site(s) in Kenya KISUMU CRS |
Not recorded |
View |
10. |
ECCT/17/09/04 | A5354 A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Brian Baker Site(s) in Kenya KISUMU CRS |
Not recorded |
View |